Rewind Therapeutics launched to treat MS

A new Belgian start-up has been launched with Series A funding of €15.2 million to develop re-myelinating therapies for patients with multiple sclerosis and other myelin-related diseases. Called Rewind Therapeutics SA, the company is located in Leuven.

Full text available to subscribers only. Click here for information on subscribing to MedNous.